AGÕæÈ˹ٷ½

STOCK TITAN

[SCHEDULE 13G] Trevi Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Rubric Capital Management LP
Signature:/s/ Michael Nachmani
Name/Title:Michael Nachmani / Chief Operating Officer
Date:07/09/2025
David Rosen
Signature:/s/ David Rosen
Name/Title:David Rosen, Individually
Date:07/09/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

Trevi Therapeutics

NASDAQ:TRVI

TRVI Rankings

TRVI Latest News

TRVI Latest SEC Filings

TRVI Stock Data

974.21M
107.24M
0.72%
92.72%
8.34%
Biotechnology
Pharmaceutical Preparations
United States
NEW HAVEN